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To the Editor:
The importance of submitting 
data of clinical response to epidermal 
growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) in patients with 
uncommon EGFR mutations has been 
encouraged.1 In view of this, we present 
two cases of a rare EGFR mutation that 
appears to confer resistance to TKIs.
Case 1, a 56-year-old Afro-
Caribbean male presenting with hemop-
tysis, breathlessness, and weight loss. 
Performance status was 1, with no sig-
nificant past medical history and 1 pack 
year smoking history. Imaging showed 
a right middle lobe mass, mediastinal 
lymphadenopathy, and liver metastases. 
Mediastinal biopsy confirmed poorly 
differentiated adenocarcinoma (TTF+, 
CK7+, and CK20−). EGFR mutation 
analysis of selected regions of exons 18 
to 21, using real-time polymerase chain 
reaction, revealed missense mutation in 
exon 20 at nucleotide 2303 resulting in 
serine to isoleucine substitution at codon 
768. After commencing gefitinib 250 mg 
daily, computed tomography scan after 6 
weeks showed disease progression with 
new liver and bony metastases. Within 2 
weeks of switching to 3-weekly peme-
trexed (500 mg/m2) and cisplatin (70 mg/
m2), his exercise tolerance improved and 
imaging after 4 cycles demonstrated a 
partial response. Unfortunately, he was 
admitted to hospital with pneumonia after 
his third cycle of maintenance peme-
trexed (500 mg/m2) and died 4 days later.
Case 2, a 65-year-old Caucasian 
female presenting with acute onset 
shortness of breath. Performance status 
was 0, with no significant past medi-
cal history and 20 pack year smoking 
history. Imaging showed a right lower 
lobe pulmonary embolism with inci-
dental right upper lobe mass, right 
lung metastases, and extensive subcari-
nal, mediastinal, and retroperitoneal 
lymphadenopathy. Mediastinal biopsy 
confirmed poorly differentiated adeno-
carcinoma (TTF+, CK7+, and CK20−). 
EGFR mutation analysis reported 
the same exon 20 missense mutation 
described in case 1.
She had six cycles of pemetrexed 
(500 mg/m2) and cisplatin (70 mg/m2) che-
motherapy with a good partial response. 
Within 2 months of commencing treat-
ment with maintenance erlotinib (150 mg 
daily), imaging showed progression of 
all lesions. Despite early disease stabili-
zation on switching to oral vinorelbine 
(60 mg/m2), computed tomography scan 
after 4 months revealed further progres-
sion. She was unfit for further treatment 
and died 2 months later.
A number of rare EGFR mutations 
exist to which response to targeted therapy 
is unclear. The exon 20 missense mutation 
S768I is one of these. In Asian populations, 
prevalence of this mutation is less than 5% 
although it is more commonly seen in 
combination with other mutations.2 In our 
region, prevalence of this single mutation 
is 1.5% (unpublished data).
In vitro, cells expressing S768I 
mutation are less sensitive to EGFR-
targeted treatment than wild-type cells.3 
However, reports of clinical outcome in 
these patients are conflicting.4,5
Our two cases add to the evidence 
that the S768I mutation causes insensitiv-
ity to TKI therapy. However, both cases 
did show response to platinum-based 
chemotherapy. Furthermore, these cases 
continue to highlight the importance of 
publishing treatment response data for 
cases of rare EGFR mutant lung cancers 
to guide clinical decision making.
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To the Editor:
While HRAS mutations have been 
identified in a few cases of non–small-cell 
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lung cancer (NSCLC), the clinical course 
of patients with NSCLC with HRAS muta-
tions has not been described. The following 
case discusses a patient with an HRAS-
positive adenocarcinoma of the lung who 
experienced rapid clinical decline.
CASE PRESENTATION
A 79-year-old male former 
smoker with a history of resected World 
Health Organisation (WHO) Grade I 
sphenoid meningioma presented to the 
emergency room, whereupon a com-
puted tomography chest showed a 3-cm 
soft-tissue density in the anterior seg-
ment of the right upper lobes (Figs. 1 
and 2). Moderately differentiated adeno-
carcinoma was confirmed by computed 
tomography-guided biopsy of the mass.
In September 2010, the patient 
underwent mediastinoscopy followed 
by right upper lobectomy. Final patho-
logic staging was T2aN0M0 (stage Ib) 
adenocarcinoma, large-cell subtype. 
The patient was treated with four cycles 
of pemetrexed and carboplatin.
In July 2011, 10 months after com-
pleting the right upper lobectomy, the 
disease had metastasized to his brain. He 
underwent craniotomy for the left tem-
poral lobe mass, followed by stereotactic 
radiosurgery of additional CNS lesions. 
Pathology of the temporal lobe lesion 
revealed poorly differentiated adenocar-
cinoma consistent with metastasis from 
a lung primary (Fig. 3). Multiplex poly-
merase chain reaction/mass spectroscopy 
(MassARRAY system) was performed, 
testing for 647 known gene mutations 
in solid tumors (among 53 genes), and 
revealed one mutation, HRAS Q61L 
(Table 1). The patient’s previously 
resected meningioma was also tested for 
mutations using the same multiplex poly-
merase chain reaction/mass spectroscopy 
platform previously described, and no 
mutations were found in the meningi-
oma, including no HRAS mutations.
Additional imaging revealed 
metastatic multiple bony lesions and 
innumerable liver lesions and bilat-
eral adrenal lesions. The patient had an 
Eastern Cooperative Oncology Group 
performance status of three and was not a 
candidate for systemic palliative chemo-
therapy. The patient died in January 2012.
DISCUSSION
The case demonstrates a patient 
diagnosed with adenocarcinoma with 
HRAS mutation. The patient had a rapid 
progression from stage IB disease to 
metastatic adenocarcinoma and death.
Ras mutations are detectable in 
approximately 20% of lung cancers, 
with KRAS mutations representing 
90% of those mutations. KRAS muta-
tions are associated with a poor overall 
prognosis1 in NSCLC.
HRAS mutations have been 
documented in various cancer types 
(including cervical, salivary gland car-
cinoma, head and neck squamous cell 
carcinoma, melanoma, transitional 
cell carcinoma of the bladder, prostate 
adenocarcinoma, breast, and both soft-
tissue and osteosarcomas).2,3 HRAS 
mutations have also been described 
in Costello syndrome, also known as 
faciocutaneoskeletal syndrome, a rare 
genetic disorder characterized by men-
tal retardation, cardiac abnormalities, 
and distinct facial features.4
HRAS mutations represent 1% 
of all mutations in NSCLC.5 Although 
infrequent, the role of HRAS in the 
pathogenesis of NSCLC is uncertain. 
Our patient with HRAS mutation had 
rapid progression from early stage 
NSCLC and died from metastatic dis-
ease less than 18 months after diag-
nosis. Additional cases with HRAS 
mutation are needed to evaluate the 
clinical behavior and prognostic fea-
tures of HRAS mutant NSCLC. For 
this patient, the possibility of HRAS 
mutant NSCLC causing rapid disease 
progression and death from metastatic 
NSCLC raises the likelihood that 
HRAS mutations in NSCLC tumors 
are aggressive and associated with poor 
overall prognosis, similar to KRAS 
mutant NSCLC. Further research and 
description of clinical cases are needed 
for improved understanding of this 
genetic mutation in NSCLC.
FIGURE 1.  Computed tomography chest with 3-cm soft-tissue density in the  anterior 
segment of the right upper lobe.
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FIGURE 2.  Positron emission tomo graphy scan, notable for increased uptake 
(SUV 8) in the right upper lobe lesion only.
FIGURE 3.  Histology of CNS metastases, adenocarcinoma of lung origin.
TABLE 1.  Mutation Analysis Performed, 
Only Positive for HRAS Q61L Mutation
Mutation Analyzed Result
HRAS, Q61L POS
AKT1 Neg
CTNNB1 Neg
FGFR1 Neg
GNAS Neg
KRAS Neg
NRAS Neg
PIK3R4 Neg
SOS1 Neg
AKT2 Neg
EGFR Neg
FGFR2 Neg
MAP2K1 Neg
NTRK1 Neg
PIK3R5 Neg
STAT1 Neg
AKT3 Neg
ERBB2 Neg
FGFR3 Neg
IDH1 Neg
MAP2K2 Neg
NTRK2 Neg
PKHD1 Neg
TEC Neg
ALK Neg
ERCC6 Neg
FGFR4 Neg
IDH2 Neg
MAP2K7 Neg
NTRK3 Neg
PRKCB1 Neg
TP53 Neg
BRAF Neg
FBX4 Neg
FOXL2 Neg
IGF1R Neg
MET Neg
PDGFRA Neg
RAF1 Neg
CDK4 Neg
FBXW7 Neg
GNA11 Neg
KDR Neg
MYC Neg
P1K3CA Neg
RET Neg
CSF1R Neg
FES Neg
GNAQ Neg
KIT Neg
NEK9 Neg
PIK3R1 Neg
SMO Neg
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CASES PRESENTATION
In July of 2012, an Asian, 
52-year-old male smoker presented 
with a right cervical lymph node. 
A stage IV adenocarcinoma in the 
right lung; lymphangitis carcinoma-
tosis; mediastinal, cervical, and sus-
clavicular lymph nodes; and sacrum 
and hip bone osteoblastic metastases 
were diagnosed. Two-point mutations 
in exon 18 of the EGFR, p.I706T, and 
p.G719A were detected. Gefitinib treat-
ment started in August of 2012. After 3 
months, computed tomography -scan 
showed a partial response (Fig. 1).The 
clinical response was maintained under 
gefitinib treatment with 22 months of 
follow up.
The second patient was a 
Caucasian, 58-year-old female smoker, 
referred in February of 2013. A stage IV 
lung adenocarcinoma, in the lower right 
lobe, with mediastinal lymph nodes 
as well as cerebral and right adrenal 
gland metastases was diagnosed. Two-
point mutations in exon 18, p.E709K 
and p.G719A, were detected. Erlotinib 
treatment and whole brain radiotherapy 
began. After 2 months, the patient’s 
performance status improved and com-
puted tomography scan demonstrated 
a partial response on brain metastases 
and primary tumor. Then she presented 
with a progression of extracerebral 
metastases. Erlotinib was stopped. 
A chemotherapy combining cispla-
tin and pemetrexed was administered. 
In September of 2013, due to disease 
progression, carboplatin and paclitaxel 
were proposed. The patient presented 
a stable disease for 4 months and then 
progressed. She died 11 months after 
diagnosis of metastatic disease.
DISCUSSION
The clinical significance of 
EGFR complex mutations differs 
whether complex mutations include the 
most frequent mutations or not. Hata et 
al5 showed that tumours with complex 
mutations, including deletion of exon 19 
or L858R point mutation, had the same 
response rate to EGFR-TKI than those 
with the same mutations alone. Wu et al2 
showed that patients with rare and com-
plex mutations, compared with patients 
with classic or rare mutation alone or 
classic mutation with rare mutations, 
had a worse response rate to EGFR-
TKI (25% versus 74.8, 68.8, and 80%, 
respectively) and a poorer progression-
free survival (1.4 versus 11.9, 8.1, and 
8.0 months). Beau-Faller et al6 showed 
that EGFR-TKI efficacy was similar or 
slightly poorer in patients with complex 
mutations including p.G719X. Keam 
et al3 reported only two double muta-
tions in exon 18, including the G719A 
+ I706T, in a series of 306 patients. The 
overall survival of this patient, treated 
with erlotinib, was 53 months.3 This is 
the first description of the p.E709K + 
p.G719A mutation.
To date, the behavior of these 
NSCLCs with complex mutations are 
not completely understood. The report 
of these rare and complex mutations and 
their response to EGFR-TKI should be 
very useful for the constitution of well-
annotated databases and to improve the 
knowledge of their specific response to 
EGFR-TKI.
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FIGURE 1.  Computed tomography scan of chest of patient 1 (left) before treat-
ment and (right) after 3 months of gefitinib treatment.
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To the Editor:
In non–small-cell lung cancer 
(NSCLC) besides the common exons 
19 and 21 EGFR-activating muta-
tions (>90%), exon 18-point muta-
tions (mainly p.G719X) are rare (4%).1 
They are associated with a favorable 
response rate to EGFR tyrosine kinase 
inhibitors (EGFR-TKI),2,3 but are 
lower than common mutations.4 More 
than one mutation per sample repre-
sents complex mutations. Their clini-
cal significance is uncertain, because 
they are rare (3.4–6.9%).2,3 Here, we 
present two cases of NSCLC with rare 
complex mutation that respond differ-
ently to EGFR-TKI.
